Season's Savings | ₹5/mo for 3 months
₹199/month after first 3 months. Renews automatically. Terms apply.
TSC Talks 3.0~What Did We Sign? Data, Consent, and the Gene Therapy Machine
Failed to add items
Sorry, we are unable to add the item because your shopping basket is already at capacity.
Add to cart failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
-
Narrated by:
-
Written by:
About this listen
- Dear TSC Alliance Leadership and Natural History Database Steering Committee,.pdf
- TSC Alliance contact: biosample@tscalliance.org
- Host contact: Jill Woodworth (pjlacy6@gmail.com)
- MA AG consumer complaint form: mass.gov/how-to/file-a-consumer-complaint
- Apertura Gene Therapy press release (May 2026)
- TSC Alliance NHD page: tscalliance.org
- Van Andel Institute Biorepository: Grand Rapids, MI
- Key terms: AAV, TSC1, TSC2, vector sizing, DRG toxicity, antibody neutralization, 15-year FDA follow-up mandate
---
KEY DEFINITIONS
*AAV Capsid Delivery Platform: An adeno-associated virus (AAV) vector system engineered to deliver functional genetic material into host cells. In this context, it utilizes a viral shell (capsid) to cross specific biological barriers and target neural tissues. Key operational constraints and clinical considerations include:
*Packaging Limits: AAV vectors have a strict genetic payload capacity of approximately 4.7 kilobases total (including ITRs), leaving roughly 4.4 kilobases for the transgene cassette. Genes exceeding this length (such as full-length TSC2, at ~4.3 kb coding sequence plus necessary promoter and polyA signals) present significant packaging challenges.
*Immune Response & Irreversibility:** Exposure to an AAV capsid triggers neutralizing antibody production by the patient's immune system, permanently barring subsequent administration of AAV-based treatments.
*Monitoring Requirements: Regulatory standards (such as FDA mandates) require extended long-term follow-up monitoring—typically lasting up to 15 years—to evaluate long-term safety, potential hepatotoxicity, and dorsal root ganglion (DRG) toxicity.
I discuss the TSC gene therapy agreement and the TSC Natural History Database (NHD), raising questions about consent, data governance, and long-term impacts on families. I explains the NHD’s scope (running since 2006 with 2,700+ participants, clinical histories and biosamples stored at Van Andel Institute, and thousands of samples distributed to researchers) and critiques the May 2026 TSC Alliance partnership with for-profit Apertura Gene Therapy, backed by Deerfield Management, to develop an AAV gene replacement therapy delivering TSC1/TSC2 to the brain. I outline concerns about lack of reconsent when minors become adults, unclear withdrawal processes, financial protections for participants, and under-communicated risks of AAV therapies (high cost, permanent antibody barrier to future AAV dosing, 15-year monitoring, and TSC2 packaging constraints). I describe a certified letter demanding written answers and offers steps for parents to request consent forms, ask about withdrawal, and file complaints if needed.
00:00 Intro and Big Questions
01:57 What We Signed
02:34 Inside the NHD Database
03:47 Apertura Partnership Explained
04:59 Consent and Governance Gaps
06:30 Gene Therapy Risks Breakdown
09:29 My Certified Letter
09:37 Five Demands for Transparency
12:35 What You Can Do Now
14:48 Final Thoughts and Wrap Up
https://aperturagtx.com/news/apertura-gene-therapy-and-the-tsc-alliance-announce-collaboration-to-advance-gene-therapy-programs-designed-to-treat-tuberous-sclerosis-complex-tsc/
https://www.prnewswire.com/news-releases/apertura-gene-therapy-showcases-the-progress-of-its-novel-human-transferrin-receptor-aav-capsid-tfr1-capx-and-preclinical-programs-for-tuberous-sclerosis-complex-tsc-at-the-american-society-of-gene-and-cell-therapy-asgct-ann-302448607.html
https://www.prnewswire.com/news-releases/tsc-alliance-and-apertura-gene-therapy-complete-preclinical-pilot-study-evaluating-aav-gene-therapy-approach-designed-for-tsc1-302838523.html
Become a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.
adbl_web_anon_alc_button_suppression_t1
No reviews yet